Pharmas Market Video Gallery
The FDA is holding meetings into big pharma's possible use of social media to sell their products. CNBC's Mike Huckman h...
Big pharma is embracing social media, but how much can or should a tightly regulated sector be able to say on Facebook o...
More Videos
SPECIAL REPORT
MOST SHARED
- Warren Buffett and Bill Gates Share Their 'Optimism' With Eager Columbia Business Students
- Cities With the Most Home Price Reductions
- Disney Profit, Sales Top Street Forecasts; Shares Jump
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Meet The Leaders of the New Retail Revolution
- Disney CFO and Parks Chief to Swap Roles
- Despite Rhetoric, Obama Has Limited Options To Boost Jobs
- Is Euphoric Market Ignoring Warning Signs?
- Housing Recovery 'Still In Uncharted Territory': HUD Secretary
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Gold Is a Bad Inflation Hedge—Like Oil: Stock Picker
- Intel's Andy Bryant Offers An Explanation
- US 'Actively Working' on Weaker Dollar: Fund Manager
- Options Boil on Biotech Buyout Rumors
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Activision Blizzard's "Modern Warfare 2" Sales Break Records
- 5-Star Manager's 5 Stocks for Changing Markets
- What's The Forecast from Retailers? Proceed With Caution
- Job Market Politics to Keep Interest Rates Low
- AIG, Symbol of Crisis, Watches Its Stock Zoom Back
- Disney Profit, Sales Top Street Forecasts; Shares Jump
- Bill Gates Praises Apple's Jobs for 'Saving the Company'
- Cities With the Most Home Price Reductions
- Cramer: The Real Reason Stocks Fell Thursday
- Is Euphoric Market Ignoring Warning Signs?
- Video Game Sales Plunge, but Have They Hit Bottom?
- Despite Rhetoric, Obama Has Few Options to Boost Jobs
RSS FEED
» Help
powered by digg
Pharma's Market
Text Size 
Apr.26
11:35 AM ET
Thursday, 26 Apr 2007
Tamiflu Turnaround
 |
AP |
Roche today is announcing that it's cutting back production of Tamiflu. When bird flu stories and fears started reaching critical mass more than a year ago, Roche came under considerable criticism for not being able to make enough Tamiflu to meet the sudden spike in demand.
The drug has been shown to work in fighting off seasonal and avian flu strains, but there are scattered reports of patient resistance to Tamiflu. Roche responded by quickly expanding its worldwide manufacturing capacity. Soon after, it announced that it could make as much as 400 million courses of Tamiflu per year. (Gilead Sciences [GILD Loading... ()
] discovered Tamiflu and gets royalties on sales from Roche.)But to date, Roche says it has received orders from governments, health agencies and corporations for a total of 215 million courses. So it's scaling back unless or until demand picks up. I suspect that could happen if or when an infected bird is confirmed to have shown up on North American shores.
GlaxoSmithKline [GSK Loading... ()
] makes a much smaller-selling inhalable flu drug called Relenza. And BioCryst Pharmaceuticals [BCRX
Loading...
()
] is testing an injectable antiviral called Peramivir (purr-am-uh-veer).Questions? Comments?
© 2009 CNBC, Inc. All Rights Reserved
POPULAR PHARMA'S MARKET POSTS
MORE FROM CNBC
TOPIC : Pharmaceuticals
Data is a real-time snapshot *Data is delayed at least 15 minutes